Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q35477363

about

Clinical immunologic approaches for the treatment of Alzheimer's disease Intravenous immunoglobulin for Alzheimer's disease 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease Active and passive immunotherapy for neurodegenerative disorders The immunotherapy of Alzheimer's disease Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Intravenous immunoglobulin and Alzheimer's disease: what now?Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease.IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies Cellular and molecular mechanisms of immunomodulation in the brain through environmental enrichment.Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool Anti-amyloidogenic activity of IgGs contained in normal plasma Amyloid-beta immunotherapy for Alzheimer's disease Drug development for Alzheimer's disease: where are we now and where are we headed?Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Immunogenic properties of amyloid beta oligomers.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Bapineuzumab Amyloid-ß-directed immunotherapy for Alzheimer's disease.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment.Autoreactive-Aβ antibodies promote APP β-secretase processing.Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome.Alzheimer's disease and the amyloid cascade hypothesis: a critical review.The immune system, amyloid-beta peptide, and Alzheimer's disease.Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.Immunization therapy in Alzheimer's disease.

P2860

Q22241380-B9DF9E2A-4444-4657-96E5-0C121C95AF33 Q24188215-94FBAF34-41A8-4366-8541-14D48EDDF1E3 Q24606651-2582C41A-9E68-4F9C-B35D-7467F44F8A09 Q24657879-C66025B4-9966-4AE4-8A18-A77C3BA5C99E Q24804900-541FD091-EB15-42DC-89B6-21194730935A Q26740418-0DEFA06D-B8BC-4B80-AA93-C293537FA553 Q26781578-D90C9F55-6AB8-40F6-B7E2-79EB85D103F0 Q26866006-BBDC1AB2-2324-43BB-9162-50A2E8F538AC Q27000371-6862C1F7-2943-4775-9AFA-0C08144E1D7D Q27311810-87EFF46A-B976-455A-9758-F3C17387B9E6 Q27497796-47C237CE-7429-4446-A52E-34BE9D24E43E Q28748498-E10DF2F5-DFAB-4EE2-8F49-B9B4E8F80208 Q30439617-3006400D-2B22-41F3-8D36-6A9107ADC464 Q33381465-A9AC8537-A2BB-4F70-860B-F80B0CCE1350 Q33392254-1AB8791B-204E-4E23-84D6-8E9B18E6AE0C Q33569608-970AA8F4-EC18-40A0-AE5F-691FA6876C75 Q33886377-87F20850-50BA-4470-9739-7F86F79431B7 Q33903503-5508BCE6-5F72-40C4-88F6-F7E56542DDD1 Q33954737-AD9AE398-09FB-467D-9EBE-E7D1BFFCF0E8 Q34166256-2CDC96C5-4C3E-4E39-8B23-49CB53FC243A Q34222721-1C4163FF-328B-4339-AC1C-0CC35D37C8CC Q34329254-07083C19-23BE-449C-A9C5-145EA680C024 Q34376103-467C8355-C9D4-4DB4-8E42-07984E5549C3 Q34398107-91984044-4447-49F4-907C-999D0A0C4E74 Q34548700-8DC15F4B-0EDA-4CF9-9A10-EE9779D2E714 Q34733689-2D800F25-9615-4DB0-AFE8-A32CCC33B71F Q34974167-5A2A28AE-40EF-4119-905B-7F4E812DF943 Q35015949-CF954895-53DA-4F97-9908-B59DBD622F50 Q35184148-D017AAF0-D63A-4330-BF09-C8DC5254D887 Q35222076-5DCC84AF-3ACC-46EB-BFAE-2CE9BC62DD99 Q35540628-F9DE39B0-DD67-43D5-8CD4-9D5288356A43 Q35590968-E82E7782-393D-410D-9081-3B33653575A2 Q35753932-56669590-0B02-42AA-8ACD-B7FDA12A334C Q35754467-4F5D36CD-6C3D-4699-BE46-ACC785DDDF5C Q35855587-FA621AAC-3D82-466D-84B8-738C87355635 Q36121068-E078B063-68B6-4E09-B295-24ED0B9843D3 Q36156604-D0BAEBF4-EDBF-4285-8103-DEB0627CAB0E Q36342218-441ABC65-6A7E-48D8-9700-87757D93FF7A Q36401406-50D9A54A-CD16-4EDE-AFF0-EF353F062170 Q36492332-6634A7E1-5A0B-431A-9D67-BA7F2758D7E4

P2860

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q35477363

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Intravenous immunoglobulins co ...... atment of Alzheimer's disease.

@ast

Intravenous immunoglobulins co ...... atment of Alzheimer's disease.

@en

type

label

Intravenous immunoglobulins co ...... atment of Alzheimer's disease.

@ast

Intravenous immunoglobulins co ...... atment of Alzheimer's disease.

@en

prefLabel

Intravenous immunoglobulins co ...... atment of Alzheimer's disease.

@ast

Intravenous immunoglobulins co ...... atment of Alzheimer's disease.

@en

P1433

Q35477363-20F14187-0D83-41BC-941D-E8672FC2550E

P1476

Q35477363-23BB690A-56BF-48B8-A652-064D5DAB7D9C

P2093

Q35477363-04B45AE4-C24A-430A-96C5-8440041E3738

Q35477363-0EDB6FBC-A761-4C68-9430-3BB2C312100A

Q35477363-20EEE184-4785-49FD-903D-2AB65F05B106

Q35477363-285713AD-4865-4C2D-85F9-E6829F56E672

Q35477363-4EE283C1-929B-401B-ABD2-AE7CB263C842

Q35477363-906E2A33-F8BF-4316-9788-76F83DCEA7F1

Q35477363-919324F1-16F2-4B22-84B8-7DF282DA1789

Q35477363-91A54C59-765E-4187-94BA-CC64F1226268

Q35477363-99451714-937D-4B7F-8120-B9A3E9AC1C65

Q35477363-AFE6130C-9145-4950-A40B-130DB48B0337

P304

Q35477363-B5B36BAA-E859-4B45-A1C5-D20111A72FF5

P31

Q35477363-75B99250-CFC0-49C2-A98E-35EF2EA01919

P356

Q35477363-AC7169BB-5416-4569-BFD2-ECD1D7D4CDEE

P407

Q35477363-1E58CE1D-8245-43CF-96DA-B0599250031A

P433

Q35477363-BB13138E-9D9E-44FA-8397-2BD888D723CC

P478

Q35477363-D4CF45EA-0A0F-472C-ABDE-D40A5F1F6773

P50

Q35477363-1FBA486C-311D-4618-B5A2-2D9F6F0EA605

Q35477363-24EAAA4F-2F16-4833-A046-55EBFA5364FF

P577

Q35477363-2423F653-1847-493E-B7C2-8403C19DC75F

P5875

Q35477363-ACD55739-27E1-4A4D-8E0A-71235A439CEA

P698

Q35477363-A9618103-5A00-4D44-B7D6-002FC71D8972

P921

Q35477363-452C63B7-E91C-47C7-A096-628E44BEAFCE

Q35477363-BBCE1D29-2A1F-4ECD-984E-6961A2DF7314

P932

Q35477363-3D210D13-C09C-448B-A5FC-ACE467A58708

P356

JNNP.2003.033399

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Intravenous immunoglobulins co ...... atment of Alzheimer's disease.

@en

P2093

Brettschneider S

http://www.w3.org/2001/XMLSchema#string

Depboylu C

http://www.w3.org/2001/XMLSchema#string

Dodel RC

http://www.w3.org/2001/XMLSchema#string

Du Y

http://www.w3.org/2001/XMLSchema#string

Farlow M

http://www.w3.org/2001/XMLSchema#string

Frölich L

http://www.w3.org/2001/XMLSchema#string

Haag A

http://www.w3.org/2001/XMLSchema#string

Hampel H

http://www.w3.org/2001/XMLSchema#string

Hemmeter U

http://www.w3.org/2001/XMLSchema#string

Möller HJ

http://www.w3.org/2001/XMLSchema#string

P304

1472-1474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.2003.033399

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang H. Oertel

Stefan J Teipel

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8336617

http://www.w3.org/2001/XMLSchema#string

P698

15377700

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1738770

http://www.w3.org/2001/XMLSchema#string